NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…
On Twitter, @ACRheumDC Puts Advocacy Updates at Your Fingertips
The new Twitter account enables quick communication between ACR advocacy staff and ACR/ARP members about the policies, regulations and legislation that affect rheumatology patients and providers and how members can get involved.
ACR Advocates Against VIVIO Interference in Patient Care Decisions
The ACR is advocating against policies that threaten patient access and disrupt practice workflow, including non-medical switching, tapering patients off biologics, specialty pharmacy acquisition mandates and site-of-service restrictions.
Spring Review of 2021 State Legislative Progress
Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.
Validation of Proposed Remission and Completion Criteria for Gout Treatment
Insights into the Symptom Heterogeneity of Post-Treatment Lyme Disease
New research into the symptom heterogeneity of patients with post-treatment Lyme disease may serve as a framework to create targeted interventions or novel treatments for these patients.
COVID-19 Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab
FDA News Release—On April 16, saying that alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and…
HHS Secretary Xavier Becerra Extends Public Health Emergency
The COVID-19 public health emergency (PHE) has been extended, effective April 21. The Biden administration has indicated it will likely extend the PHE through the end of the year.
Why Community Rheumatologists Serve: Committee Work Pays Off ‘Many Times Over’
Volunteer leaders who are community rheumatologists share their thoughts about the professional and personal benefits of serving on ACR committees and encourage others to get involved.
Virtual Advocacy Saves Time, Extends Reach
As a member of the ACR Government Affairs Committee, Mohammad Kamran, MD, has embraced virtual advocacy as a way to make a difference for patients during the COVID-19 pandemic and beyond.
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 332
- Next Page »